Concert Pharmaceuticals Inc. (CNCE)

6.71
NASDAQ : Health Technology
Prev Close 6.87
Day Low/High 6.71 / 7.02
52 Wk Low/High 5.36 / 17.83
Avg Volume 222.90K
Exchange NASDAQ
Shares Outstanding 23.84M
Market Cap 163.79M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Concert Pharmaceuticals To Host KOL Webcast Event Focused On CTP-692 And Schizophrenia

Concert Pharmaceuticals To Host KOL Webcast Event Focused On CTP-692 And Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will host a conference call and webcast event with a key opinion leader in the field of psychiatry and schizophrenia on Thursday, November 14, 2019.

Concert Pharmaceuticals To Report Third Quarter 2019 Financial Results On November 7, 2019

Concert Pharmaceuticals To Report Third Quarter 2019 Financial Results On November 7, 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2019 financial results on Thursday, November 7, 2019, before the U.

Concert Pharmaceuticals Presents Positive Phase 2 Data In Alopecia Areata During Late-Breaker Session At EADV Congress

Concert Pharmaceuticals Presents Positive Phase 2 Data In Alopecia Areata During Late-Breaker Session At EADV Congress

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in...

Concert Pharmaceuticals To Provide Overview Of Clinical Pipeline At Cantor Healthcare Conference

Concert Pharmaceuticals To Provide Overview Of Clinical Pipeline At Cantor Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will be providing an overview of the Company's clinical pipeline following recent updates on the AVP-786 partnered program in a presentation at the Cantor Healthcare Conference on...

Concert Pharmaceuticals Names Jeffrey Munsie As Chief Legal Officer

Concert Pharmaceuticals Names Jeffrey Munsie As Chief Legal Officer

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has named Jeffrey A.

Concert Pharmaceuticals Completes Enrollment In Second Open Label Trial Of CTP-543 To Evaluate Once-Daily Vs. Twice-Daily Dosing In Patients With Alopecia Areata

Concert Pharmaceuticals Completes Enrollment In Second Open Label Trial Of CTP-543 To Evaluate Once-Daily Vs. Twice-Daily Dosing In Patients With Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata.

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected For Late-Breaker Oral Presentation At 2019 EADV Congress

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected For Late-Breaker Oral Presentation At 2019 EADV Congress

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata.

Concert Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For CNCE

Concert Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For CNCE

In trading on Wednesday, shares of Concert Pharmaceuticals Inc crossed above their 200 day moving average of $12.27, changing hands as high as $12.60 per share. Concert Pharmaceuticals Inc shares are currently trading up about 12.2% on the day.

Concert Pharmaceuticals Reports Positive CTP-543 Results From Phase 2 Alopecia Areata Trial

Concert Pharmaceuticals Reports Positive CTP-543 Results From Phase 2 Alopecia Areata Trial

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced final topline results from its recently completed dose-ranging Phase 2 trial evaluating its investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune...

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The H.

Concert Pharmaceuticals Reports Second Quarter 2019 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2019 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2019.

Concert Pharmaceuticals To Report Second Quarter 2019 Financial Results On August 1, 2019

Concert Pharmaceuticals To Report Second Quarter 2019 Financial Results On August 1, 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2019 financial results on Thursday, August 1, 2019, before the U.

Concert Pharmaceuticals Reports Positive Results From Phase 1 Studies Evaluating CTP-692 In Healthy Volunteers

Concert Pharmaceuticals Reports Positive Results From Phase 1 Studies Evaluating CTP-692 In Healthy Volunteers

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia.

Concert Pharmaceuticals Completes Enrollment In Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals Completes Enrollment In Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Concert Pharmaceuticals Announces Initiation Of New Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals Announces Initiation Of New Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The UBS Global Healthcare Conference on May 21, 2019 at 10:00 a.

Concert Pharmaceuticals Reports First Quarter 2019 Financial Results

Concert Pharmaceuticals Reports First Quarter 2019 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2019.

Concert Pharmaceuticals Names Jesper Høiland To Its Board Of Directors

Concert Pharmaceuticals Names Jesper Høiland To Its Board Of Directors

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately.

Concert Pharmaceuticals To Report First Quarter 2019 Financial Results On May 2, 2019

Concert Pharmaceuticals To Report First Quarter 2019 Financial Results On May 2, 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2019 financial results on Thursday, May 2, 2019, before the U.

Concert Pharmaceuticals To Present CTP-543 Phase 2 Interim Data In Alopecia Areata At 2019 World Congress For Hair Research Annual Meeting

Concert Pharmaceuticals To Present CTP-543 Phase 2 Interim Data In Alopecia Areata At 2019 World Congress For Hair Research Annual Meeting

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11 th Annual World Congress for Hair...

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia.

Concert Pharmaceuticals Is Now Oversold (CNCE)

Concert Pharmaceuticals Is Now Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Announces Decision From Patent Trial And Appeal Board In IPR Proceeding

Concert Pharmaceuticals Announces Decision From Patent Trial And Appeal Board In IPR Proceeding

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.

First Week Of May 17th Options Trading For Concert Pharmaceuticals (CNCE)

First Week Of May 17th Options Trading For Concert Pharmaceuticals (CNCE)

Investors in Concert Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CNCE options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

CNCE: Insiders Vs. Shorts

CNCE: Insiders Vs. Shorts

The most recent short interest data was recently released for the 03/15/2019 settlement date, and Concert Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 4.66 "days to cover" versus the median component at 4.33. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

CNCE Makes Notable Cross Below Critical Moving Average

CNCE Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Concert Pharmaceuticals Inc crossed below their 200 day moving average of $15.17, changing hands as low as $14.21 per share. Concert Pharmaceuticals Inc shares are currently trading off about 7.4% on the day.

First Week Of CNCE July 19th Options Trading

First Week Of CNCE July 19th Options Trading

Investors in Concert Pharmaceuticals Inc saw new options begin trading this week, for the July 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 123 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Concert Pharmaceuticals To Present At Upcoming Oppenheimer Healthcare Conference

Concert Pharmaceuticals To Present At Upcoming Oppenheimer Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Oppenheimer 29 th Annual Healthcare Conference on March 19, 2019 at 1:00 p.

TheStreet Quant Rating: D (Sell)